A comparative investigation of the interaction and pharmacokinetics of hemoglobin with berberine and its oxymetabolite

Han-Bin Chen, Chao-Dan Luo, Gao-Xiang Ai, Yong-Fu Wang, Cai-Lan Li, Li-Hua Tan, Simon Ming-Yuen Lee, Alex Kwok-Kuen Cheung, Zi-Ren Su, Xiao-Li Wu (Corresponding Author), Jian-Hui Xie (Corresponding Author), Hui-Fang Zeng (Corresponding Author)

Research output: Journal article publicationJournal articleAcademic researchpeer-review

5 Citations (Scopus)


Berberine (BBR), isolated from Coptis chinensis, is one type of isoquinoline alkaloids. BBR exerts numerous of bioactivities but the plasma concentration is really low. In our previous study, a new oxymetabolite (OBB) has been discovered and showed superior anti-inflammatory effect comparing with BBR. The aim of this study is to investigate the interaction, metabolite and pharmacokinetics of BBR with hemoglobin. Sprague-Dawley rats were used to carry out the interaction, metabolite and pharmacokinetics of BBR and OBB in vivo. Fluorescence spectra were used to analyse the interaction in vitro. Results showed that OBB could be generated after intravenous injection or incubating with BBR in vitro and in vivo; Both BBR and OBB exerted much stronger binding interaction with hemoglobin than plasma and affect the conformation of bovine hemoglobin and change the fluorescence spectral properties; BBR and OBB were mainly presented and transported in the proteins-bound form. These results provide a new insight to understand the dynamic equilibrium of BBR and OBB within body from the perspective of new metabolic pathways.

Original languageEnglish
Article number114032
JournalJournal of Pharmaceutical and Biomedical Analysis
Publication statusPublished - 30 May 2021


  • Berberine
  • Hemoglobin
  • Interaction
  • Metabolite
  • Pharmacokinetics

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this